{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:57:09Z","timestamp":1790510229331,"version":"4.1.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The purpose of this randomized, multicenter, open-label study was to compare the continuous infusion of piperacillin-tazobactam with the standard intermittent infusion in 262 hospitalized patients with complicated intra-abdominal infections. Within 1 day of surgical intervention, eligible patients were randomized (1:1) to piperacillin-tazobactam 12 g\/1.5 g administered continuously over 24 h or 3 g\/0.375 g administered over 30 min intermittently every 6 h for 4 to 14 days. The demographics of the patients in the groups were similar, with a median APACHE II score of 7 and a median length of hospitalization of 7 days. Among 167 clinically evaluable patients, 86.4% and 88.4% of the patients treated with the continuous infusion and the intermittent infusion, respectively, were clinically cured or improved at the test-of-cure visit (\n            <jats:italic>P<\/jats:italic>\n            = 0.817). Bacteriological success was observed in 83.9% and 87.9% of patients (\n            <jats:italic>P<\/jats:italic>\n            = 0.597) in the two groups, respectively, and no differences in bacteriological response by pathogen were noted. Defervesence and white blood cell count normalization occurred in the majority of patients within 3 days and were similar between patients receiving the continuous infusion and those receiving the intermittent infusion. Drug-related adverse events were generally mild and were reported in similar numbers of patients in each arm of the trial. The results of this study support continuous infusion as a safe and reasonable alternate mode of administration of piperacillin-tazobactam for the treatment of complicated intra-abdominal infection.\n          <\/jats:p>","DOI":"10.1128\/aac.00329-06","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T20:58:50Z","timestamp":1161809930000},"page":"3556-3561","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":112,"title":["Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection"],"prefix":"10.1128","volume":"50","author":[{"given":"William\u2009K.","family":"Lau","sequence":"first","affiliation":[{"name":"The Queens Medical Center, Honolulu, Hawaii"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mercer","sequence":"additional","affiliation":[{"name":"University of Texas, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal M.","family":"Itani","sequence":"additional","affiliation":[{"name":"Boston VA Health Care System and Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Kuti","sequence":"additional","affiliation":[{"name":"Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Wyeth Pharmaceuticals, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Dana","sequence":"additional","affiliation":[{"name":"Wyeth Pharmaceuticals, Collegeville, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00019048-199812000-00007","volume":"7","year":"1998","unstructured":"Ambrose, P. G., R. Quintiliani, C. H. Nightingale, and D. P. Nicolau. 1998. Continuous vs. intermittent infusion of cefuroxime for the therapy of community-acquired pneumonia. Infect. Dis. Clin. Pract.7:463-470.","journal-title":"Infect. Dis. Clin. Pract."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02014330"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.691"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90242-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.08.012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)87978-3"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0149-2918(02)80021-2","volume":"24","year":"2002","unstructured":"Burgess, D. S., and T. Waldrep. 2002. Pharmacokinetics and pharmacodynamics of piperacillin\/tazobactam when administered by continuous infusion and intermittent dosing. Clin. Ther.24:1090-1104.","journal-title":"Clin. Ther."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.12.2577"},{"key":"e_1_3_2_10_2","first-page":"937","year":"1988","unstructured":"Daenen, S., and H. de Vries-Hospers. 1988. Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lanceti:937.","journal-title":"Lancet"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02310354"},{"key":"e_1_3_2_12_2","first-page":"1454","year":"1989","unstructured":"David, T. J., and J. Devlin. 1989. Continuous infusion of ceftazidime in cystic fibrosis. Lanceti:1454-1455.","journal-title":"Lancet"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2146\/ajhp050323","volume":"63","year":"2006","unstructured":"DeRyke, C. A., J. L. Kuti, D. Mansfield, A. Dana, and D. P. Nicolau. 2006. Pharmacoeconomics of continuous versus intermittent infusion piperacillin\/tazobactam for the treatment of hospitalized patients with complicated intra-abdominal infection. Am. J. Health Syst. Pharm.63:750-755.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1093\/ajhp\/60.22.2321","volume":"60","year":"2003","unstructured":"Florea, N. R., S. Kotapati, J. L. Kuti, E. C. Geissler, C. H. Nightingale, and D. P. Nicolau. 2003. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am. J. Health Syst. Pharm.60:2321-2327.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.7.471.33665"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/ajhp\/54.14.1614","volume":"54","year":"1997","unstructured":"Hitt, C. H., C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 1997. Cost comparison of single daily iv doses of ceftriaxone versus continuous infusion of cefotaxime. Am. J. Health Syst. Pharm.54:1614-1618.","journal-title":"Am. J. Health Syst. Pharm."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki243"},{"key":"e_1_3_2_18_2","unstructured":"Lumpkin M. M. and D. B. Burlington. 6 July 2005 revision date. Division of Anti-Infective Drug Products Food and Drug Administration. 1992 points to consider. [Online.] http:\/\/www.fda.gov\/CDER\/guidance\/ptc.htm\n. Accessed 1 December 2005."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1592\/phco.21.6.549.34539","volume":"21","year":"2001","unstructured":"McNabb, J. J., C. H. Nightingale, R. Quintiliani, and D. P. Nicolau. 2001. Cost-effectiveness of continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy21:549-555.","journal-title":"Pharmacotherapy"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ijantimicag.2005.02.008","volume":"25","year":"2005","unstructured":"Munckhof, W. F., J. Carney, G. Neilson, J. Neilson, J. Carroll, B. McWhinney, and M. Whitby. 2005. Continuous infusion of ticarcillin-clavulanate for home treatment of serious infections: clinical efficacy, safety, pharmacokinetics and pharmacodynamics. Int. J. Antimicrob. Agents25:514-522.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","volume":"17","year":"2001","unstructured":"Nicolau, D. P., J. C. McNabb, M. K. Lacy, R. Quintiliani, and C. H. Nightingale. 2001. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int. J. Antimicrob. Agents17:497-504.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2165\/00044011-199815060-00010","volume":"15","year":"1998","unstructured":"Owens, C. A., P. G. Ambrose, R. Quintiliani, C. H. Nightingale, and D. P. Nicolau. 1998. Infusion phlebitis. Relative incidence associated with cefuroxime administered by intermittent and continuous infusion. Clin. Drug Investig.15:531-535.","journal-title":"Clin. Drug Investig."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3550-3553.2005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-199905000-00008"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.12.4920-4927.2005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000007198","volume":"45","year":"1999","unstructured":"Tessier, P. R., D. P. Nicolau, C. O. Onyeji, and C. H. Nightingale. 1999. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy45:284-295.","journal-title":"Chemotherapy"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.2.139"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/514622"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/40.1.125"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.4.831"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00329-06","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00329-06","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:58:58Z","timestamp":1645469938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00329-06"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1128\/AAC.00329-06"],"URL":"https:\/\/doi.org\/10.1128\/aac.00329-06","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"2006-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}